BMYMP Bristol-Myers Squibb Co. Forecast, Technical & Fundamental Analysis

BMYMP's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for BMYMP turned positive on January 09, 2026. Looking at past instances where BMYMP's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 07, 2026. You may want to consider a long position or call options on BMYMP as a result. In of 60 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for BMYMP moved above the 200-day moving average on December 30, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

The Aroon Indicator entered an Uptrend today. In of 119 cases where BMYMP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

BMYMP broke above its upper Bollinger Band on January 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (9.607). BMYMP has a moderately low P/E Ratio (0.000) as compared to the industry average of (24.682). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.998). BMYMP has a moderately low Dividend Yield (0.002) as compared to the industry average of (0.025). BMYMP's P/S Ratio (0.000) is slightly lower than the industry average of (3.957).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BMYMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMYMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock worse than average.